Keybank National Association OH Increases Holdings in Inovio Pharmaceuticals, Inc. (INO)
Keybank National Association OH raised its stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 41.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 42,820 shares of the biopharmaceutical company’s stock after acquiring an additional 12,578 shares during the period. Keybank National Association OH’s holdings in Inovio Pharmaceuticals were worth $271,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wasatch Advisors Inc. grew its stake in shares of Inovio Pharmaceuticals by 43.6% in the 2nd quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after buying an additional 793,306 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Inovio Pharmaceuticals by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth $1,411,000. GSA Capital Partners LLP purchased a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth $1,035,000. Finally, Virtu KCG Holdings LLC purchased a new position in shares of Inovio Pharmaceuticals in the 2nd quarter worth $556,000. Institutional investors own 24.98% of the company’s stock.
A number of equities analysts have commented on INO shares. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Maxim Group set a $12.00 price objective on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Finally, Citigroup Inc. started coverage on shares of Inovio Pharmaceuticals in a research note on Wednesday, September 6th. They issued a “buy” rating and a $10.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $19.16.
Inovio Pharmaceuticals, Inc. (NASDAQ INO) opened at $4.72 on Friday. Inovio Pharmaceuticals, Inc. has a 52 week low of $4.20 and a 52 week high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. During the same period in the prior year, the firm posted ($0.28) earnings per share. Inovio Pharmaceuticals’s revenue for the quarter was down 79.2% on a year-over-year basis. sell-side analysts anticipate that Inovio Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/11/19/keybank-national-association-oh-increases-holdings-in-inovio-pharmaceuticals-inc-ino.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Stock Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.